Connect to other sites within the UBM Medica Network
Results from a small study suggest that treatment with interferon alpha 2a could help chronic myeloid leukemia patients discontinue imatinib treatment. Image © molekuul.be / Shutterstock.com.
VEGFR, MEK, Other Inhibitors Could Treat CML in Blast Crisis
A new study using CML in blast crisis cells has identified existing anticancer agents that may provide benefit to patients with this difficult-to-treat disease.
Comorbidities in CML Patients Play Big Role in Survival
CML patients with more comorbidities at diagnosis have significantly reduced overall survival, according to an analysis of the randomized CML-Study IV.
Interferon Could Help CML Patients Stop TKI Therapy
Results from a small study suggest that treatment with interferon alpha 2a could help chronic myeloid leukemia patients discontinue imatinib treatment.
Bosutinib a Good Fourth-Line Option in CML
A small retrospective study of heavily pretreated patients with chronic myeloid leukemia found bosutinib to be a good option in the fourth-line setting.
Second-Gen TKIs Better in CML Patients With Elevated CIP2A Levels
CML patients with high CIP2A levels treated with second-generation tyrosine kinase inhibitors have better outcomes than those treated with imatinib.
Novel Imatinib/Nilotinib Strategy Could Optimize CML Treatment
A single-arm, open-label trial in Australia found that selective early switching from imatinib to nilotinib is feasible and effective in patients with CML.
RCC Drug Axitinib Could Treat TKI-Resistant CML
Researchers have shown that axitinib could be repurposed as a treatment for CML patients resistant to standard TKIs through a certain molecular mechanism.
By clicking Accept, you agree to become a member of the UBM Medica Community.